AstraZeneca: Hypertension trials

The registry lists 71 Hypertension studies with AstraZeneca as lead sponsor. 4 are open to participants now and 15 have results posted.

Phase 1 9Phase 2 6Phase 3 18Phase 4 4No phase 34(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.RecruitingNCT07686120Phase 3
• Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care SystemRecruitingNCT07361276
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureRecruitingNCT06742723Phase 3
• iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesRecruitingNCT03549754
• A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled HypertensionCompletedNCT06336356Phase 2Results posted
• A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant HypertensionCompletedNCT06168409Phase 3Results posted
• A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionCompletedNCT06034743Phase 3Results posted
• Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124CompletedNCT05459688Phase 2Results posted
• A Study of CIN-107 in Patients With Uncontrolled HypertensionCompletedNCT05137002Phase 2Results posted
• A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)CompletedNCT04519658Phase 2Results posted
• The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.CompletedNCT02336607Not applicableResults posted
• Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and HypertensionCompletedNCT01031680Phase 3Results posted
• Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)CompletedNCT00690612Phase 3Results posted
• Candesartan Effect in Second Stage Arterial HypertensionCompletedNCT00621153Phase 4Results posted
• ARIA (Atacand Renoprotection In NephropAthy Pt.)CompletedNCT00573430Phase 4Results posted
• Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and PlaceboCompletedNCT00434967Phase 3Results posted
• Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)CompletedNCT00348686Phase 4Results posted
• Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid TumoursCompletedNCT00264004Phase 2Results posted
• Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of AgeCompletedNCT00244621Phase 3Results posted
• A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.Active, not recruitingNCT07222917Phase 2
• PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of RussiaCompletedNCT06372431
• A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionCompletedNCT06344104Phase 3
• A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.Active, not recruitingNCT06268873Phase 3
• Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese PopulationCompletedNCT05966324Phase 1
• Baxdrostat Bioavailability and Bioequivalence StudyCompletedNCT05963009Phase 1
• Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic ImpairmentCompletedNCT05961397Phase 1
• Phase 1 Study to Determine the Metabolism and Clearance of BaxdrostatCompletedNCT05961384Phase 1
• Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy SubjectsCompletedNCT05526690Phase 1
• Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy SubjectsCompletedNCT05500820Phase 1
• Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal FunctionCompletedNCT05470725Phase 1
• Congenital Malformations and Maternal Use of Anti-hypertensive Medication in the United KingdomCompletedNCT02459990
• Centralised Pan-Algerian Survey on the Undertreatment of HypercholesterolemiaCompletedNCT01768403
• To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic HypertensionTerminatedNCT01403922Phase 1
• Achievement of Goal Resting Heart Rate on B-blockers in Patients With Stable Angina and HypertensionCompletedNCT01321242
• COMPLIANCE An Observational Study of Treatment Compliance and Quality of Life in Patients on Antihypertensive MedicationCompletedNCT01274494
• An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial HypertensionCompletedNCT01201980
• Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of HypertensionCompletedNCT01152567
• To Assess Adherence to the Treatment and Quality of Life in Patients With HypertensionCompletedNCT00944489
• Metabolic Syndrome Observation on a Regional BasisCompletedNCT00933010
• Evaluation of Target Organs Impairment on Patients Suffering From High Blood PressureCompletedNCT00925470
• Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).CompletedNCT00891124
• European Study of Cardiovascular RiskCompletedNCT00882336
• Regional Observation of the Metabolic SyndromeCompletedNCT00874952
• Treatment of Hypertension in Primary Care in SpainCompletedNCT00868881
• Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate HypertensionCompletedNCT00861016Phase 4
• Management of Cardiovascular Risk FactorsCompletedNCT00848380
• Bioequivalence Study in Healthy SubjectsCompletedNCT00844324Phase 1
• Evaluation of Atacand® (Candesartan) in Daily Medical PracticeCompletedNCT00837720
• National Survey on HypertensionCompletedNCT00804167
• Survey on the Treatment of Hypertension in Patients With Type 2 DiabetesCompletedNCT00803660
• In-practice Evaluation of Atacand 16mg Antihypertensive EffectCompletedNCT00802542
• Retrospective Treatment Pattern Survey for the Patient With and Without History of StrokeCompletedNCT00785057
• Hypertensive Treatment Pattern Survey for Type II Diabetes Mellitus Patients With Complication and HypertensionCompletedNCT00771069
• Analysis of Antihypertensive Treatment EfficacyTerminatedNCT00767247
• National Survey on Hypertension in General Practitioner (GP) ConsultationCompletedNCT00695656
• National Survey on Hypertension at HospitalCompletedNCT00695266
• National Survey on Hypertension in Cardiologic Private PracticeCompletedNCT00695175
• Retrospective Treatment Pattern Survey for the Patients With Hypertension and StrokeCompletedNCT00681707
• Retrospective Survey for Patients With Hypertension and Diabetes MellitusCompletedNCT00681278
• Factorial Study of Metoprolol Succinate TOPROL-XL (324A)CompletedNCT00642096Phase 3
• Atacand (Candesartan) Real Life StudyCompletedNCT00620178
• Efficacy Observational Study of Candesartan Cilexetil on Hypertensive PatientsCompletedNCT00573742
• Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )CompletedNCT00526708
• COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand PlusCompletedNCT00526279
• Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mgCompletedNCT00383929Phase 3
• Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric SubjectsCompletedNCT00255528Phase 3
• 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric SubjectsCompletedNCT00255502Phase 3
• Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of AgeCompletedNCT00244634Phase 3
• Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of AgeCompletedNCT00244595Phase 3
• High Doses of Candesartan Cilexetil on the Reduction of ProteinuriaCompletedNCT00242346Phase 3
• TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention TrialCompletedNCT00227318Phase 3